We are pleased to present the Fall 2016 edition of Oncology & Hematology Review, expertly introduced by Prof. Michele Baccarani. This issue includes a selection of articles on immunotherapy, multiple myeloma, myeloproliferative neoplasms, and colorectal cancer.
Kathy Miller and colleagues review the current and emerging therapeutic strategies in triple negative breast cancer and Salma M AlDallal and colleague discuss sickle cell trait and renal disease.
We hope this latest edition keeps you abreast of some of the latest developments. We are currently welcoming submissions to the 2017 editions; please contact the editor for more information here.
Foreword – Oncology & Hematology Review (US), 2016;12(2):
Welcome to the fall edition of Oncology & Hematology Review, which features a broad range of articles covering topics of relevance to oncologists and hematologists, as well as the wider medical community. Included in this edition is an article by Al Dallal on sickle cell trait (SCT). While not a disease in itself, SCT is […]
An Exciting New Era in the Treatment of Myeloproliferative Neoplasms
Janus kinase/signal transducer and activator of transcription inhibition A major breakthrough in understanding the molecular drivers of myeloproliferative neoplasms (MPNs) came in 2005, with the discovery of the Janus kinase 2 (JAK2) V617F driver mutation.1 Mutated JAK activates a number of downstream pathways implicated in the proliferation and survival of malignant cells, including the signal […]
Measurable (Minimal) Residual Disease—A Meaningful Biomarker in Multiple Myeloma
Treatment paradigms in multiple myeloma are undergoing rapid transformation. Deep remissions are possible in a large number of patients with new effective therapies with or without autologous stem cell transplantation (ASCT), and this improvement is seen among all categories including newly diagnosed, relapsed refractory, elderly, as well as high-risk patients. Despite an increasingly improving proportion […]
Cancer Immunotherapy with Interleukin-2— The PROCLAIMSM Registry
Metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC) are potentially lethal cancers with overall poor prognosis. High dose interleukin-2 (HD IL-2; Proleukin®, Prometheus Laboratories Inc, San Diego, California) was approved by the US Food and Drug Administration (FDA) in 1992 for the treatment of mRCC and in 1998 for the treatment of mM. Approval […]
Advances in Colorectal and Anal Cancer Treatment Based Upon Selected ASCO 2016 Presentations— Advances in Immunotherapy and Considering the Site of the Primary Tumor in Treatment Decisions
Each June, at the oral sessions of the annual American Society of Clinical Oncology (ASCO) meeting, the ASCO Program Committee’s top ranked abstracts are presented and subjected to expert commentary. These sessions frequently signal the latest directions along which research is evolving and may set new practice standards. At the 2016 meeting, researchers spoke to […]
Cancer Immunotherapy with Interleukin-2— Current Status and Future Developments
Interleukin 2 (IL-2, Proleukin® Prometheus Laboratories Inc., San Diego, US.) is a recombinant protein that plays an essential role in the development and function of a spectrum of T cells, including regulatory T cells, a naturally occurring population of CD4+ T cells that are vital to the control of inflammatory responses.1 Consequently, IL-2 has numerous […]
Triple Negative Breast Cancer—Review of Current and Emerging Therapeutic Strategies
Triple negative breast cancer (TNBC) is defined by a lack of expression of estrogen receptor (ER) and progesterone receptor (PR), and a lack of overexpression or amplification of human epidermal growth factor 2 (HER2) on tumor cells. TNBC accounts for approximately 15–20% of all breast cancers diagnosed in the United States.1 It is more common […]
Sickle Cell Trait and Renal Disease
Sickle cell disease (SCD) is a common and serious inherited hematological disorders in humans. Globally, the disorder affects approximately 300,000 live births per year,1 and thus it is among the most important epidemiological genetic disorders in the world. SCD occurs as a result of substitution of valine for glutamic acid at the sixth amino acid […]
Invasive Epiglottic Aspergillosis Mimicking Supraglottic Laryngeal Carcinoma—A Case Report and Review of the Literature
Fungal laryngitis is an uncommon condition. The exact incidence is not well defined as very few cases have been reported in the literature. Candida is the most common pathogen involved, with Aspergillus species coming in second.1–3 Other rare causes of fungal laryngitis such as cryptococcosis, blastomycosis, and histoplasmosis have also been reported.4,5 This case report […]
European Oncology & Haematology Highlights
Developments in Advanced Prostate Cancer in 2016
In the field of detection and imaging, multiparametric-prostate magnetic resonance images (MP-MRI) were re-interpreted with the Prostate Imaging Reporting and Data System (PIRADS) V.2 and correlated with the eventual histo-pathological finding(s) in 68 patients undergoing either transrectal ultrasound (TRUS)-guided biopsy or radical prostatectomy after the MP-MRI. The findings of this study suggest that a PIRADS […]
Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review
Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!